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Human magnesium homeostasis primarily depends on the balance between intestinal absorption and renal excretion. Magnesium transport
processes in both organ systems – next to passive paracellular magnesium flux – involve active transcellular magnesium transport consisting of an
apical uptake into the epithelial cell and a basolateral extrusion into the interstitium. Whereas the mechanism of basolateral magnesium extrusion
remains unknown, recent molecular genetic studies in patients with hereditary hypomagnesemia helped gain insight into the molecular nature of
apical magnesium entry into intestinal brush border and renal tubular epithelial cells. Patients with Hypomagnesemia with Secondary Hypocalcemia
(HSH), a primary defect in intestinal magnesium absorption, were found to carry mutations in TRPM6, a member of the melastatin-related subfamily
of transient receptor potential (TRP) ion channels. Before, a close homologue of TRPM6, TRPM7, had been characterized as a magnesium and
calcium permeable ion channel vital for cellular magnesium homeostasis. Both proteins share the unique feature of an ion channel fused to a kinase
domain with homology to the family of atypical alpha kinases. The aim of this review is to summarize the data emerging from clinical and molecular
genetic studies as well as from electrophysiologic and biochemical studies on these fascinating two new proteins and their role in human magnesium
metabolism.
© 2007 Elsevier B.V. All rights reserved.Keywords: Magnesium; Hypomagnesemia; TRPM6; TRPM7; Channel kinase; Transient receptor potential channel1. Introduction
The TRPM subgroup, named after its founding member
melastatin, of the transient receptor potential (TRP) family of
cation channels comprises eight members which exhibit an
interesting diversity of cation permeation characteristics and
activation mechanisms. Within the TRPM subfamily, two
members, TRPM6 (Chak2) and TRPM7 (ChaK1, TRP-PLIK,
LTRPC7), share the unique feature of a kinase domain belonging
to the atypical family of alpha-kinases fused to the ion channel
domain. Indeed, TRPM6 was initially cloned by Ryazanova and
colleagues who screened for homologues of eukaryotic elonga-
tion factor 2 kinase [1].
Before, its close homologue TRPM7 had been functionally
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doi:10.1016/j.bbadis.2007.03.009yielding outwardly rectifying currents when overexpressed in
heterologous expression systems [2,3]. Whereas one study
initially suggested a more nonselective conduction of sodium
and calcium [2], another report showed selectivity for calcium
and magnesium [3]. Controversy also existed towards TRPM7
gating mechanisms as well as the role of the kinase domain for
ion channel function. More recent reports argue for a regulation
of TRPM7 channel function by intracellular magnesium and
magnesium-nucleotides which is modulated by TRPM7 phos-
photransferase activity [4–6]. TRPM7 was shown to be crucial
for cellular magnesium homeostasis as targeted gene deletion of
TRPM7 in cell lines leads to intracellular magnesium deficiency
and growth arrest [4].
The critical role of TRPM6 for epithelial magnesium
transport became evident when loss-of-function mutations in
the TRPM6 gene were discovered in patients with a rare form of
hereditary hypomagnesemia called hypomagnesemia with
secondary hypocalcemia (HSH). HSH patients suffer from a
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with cerebral convulsions due to profound hypomagnesemia
early in infancy. In addition to disturbed intestinal magnesium
uptake, they also show renal magnesium wasting originating
from impaired magnesium reabsorption in the distal convoluted
tubule (DCT) [7]. In contrast to its ubiquitiously expressed
homologue TRPM7, TRPM6 was found to be intensely
expressed in intestine and kidney but also in lung and testis
[8,9]. Recent studies point to a regulation of TRPM6 expression
by nutritional magnesium [9]. Despite its obvious importance in
transepithelial magnesium reabsorption, data on functional
characteristics of TRPM6 ion channels are still controversial.
Two groups succeeded in heterologous expression of TRPM6
and describe whole cell currents strongly resembling the currents
observed for TRPM7 by Nadler and colleagues [10,11]. In
contrast, two other groups showed that functional expression of
TRPM6 in the cell membrane requires co-expression with
TRPM7 thus suggesting the formation of heteromeric ion
channels [8,12]. Therefore, although closely related, TRPM7
and TRPM6 clearly serve distinct roles in human cellular and
epithelial magnesium transport.Fig. 1. Epithelial magnesium transport in intestine and kidney. (A) Intestinal absor
saturable transcellular transport (dotted line) which is of functional importance at lo
linearly rising with intraluminal magnesium concentrations. (B) TRPM6 is a compone
their genetic defect by high oral magnesium intake. (C) Magnesium transport along
distal convoluted tubule (DCT), this nephron segment determines the final urinary ma
The DCT reabsorbs magnesium in a transcellular fashion, consisting of an apical
consisting of TRPM6/TRPM7 heteromers, and a basolateral extrusion step of unkno2. Magnesium transport in intestine and kidney
Magnesium homeostasis in humans primarily depends on the
balance between intestinal uptake and renal excretion. Magne-
sium deficiency can result from reduced dietary intake,
intestinal malabsorption or renal loss. The control of body
magnesium homeostasis primarily resides in the kidney tubules.
In the intestine, physiologic studies indicate two different
transport systems for magnesium acting in a parallel fashion:
An active transcellular transport and a passive paracellular
pathway [13,14]. The saturable transcellular uptake consists
of an apical entry into the epithelial cell through a specific ion
channel and a not yet defined basolateral extrusion mechan-
ism which probably couples magnesium export to sodium
influx [15]. Whereas at relatively low, physiologic intralum-
inal concentrations magnesium is primarily taken up via the
active transcellular route, passive paracellular magnesium
absorption linearly increases with rising intraluminal concen-
trations. Together the two transport processes yield a curvi-
linear kinetic for intestinal magnesium absorption [16]
(Fig. 1).ption follows a curvilinear kinetic resulting from two transport mechanisms: a
w intraluminal concentrations and a paracellular passive transport (dashed line)
nt of the active transcellular pathway as HSH patients are able to compensate for
the nephron. Though only a minority of filtered magnesium is reabsorbed in the
gnesium concentration, as no reabsorption takes place beyond this segment. (D)
entry into the DCT cell through a magnesium-selective ion channel, probably
wn molecular identity.
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exist serially arranged along the nephron [17]. The vast majority
of filtered magnesium is reabsorbed in the thick ascending limb
of Henle's loop (TALH) via the paracellular route. This process
is thought to be mediated by a specific divalent cation permeant
pore formed by proteins of the claudin family of tight junction
proteins. The first component of the paracellular pathway,
paracellin-1 (PCLN1) or claudin-16 (CLDN16), was discovered
by Simon and coworkers, who identified loss-of-function
mutations leading to a combined form of urinary magnesium
and calcium wasting called familial hypomagnesemia with
hypercalciuria and nephrocalcinosis (FHHNC) [18]. Very
recently, Konrad and colleagues reported the involvement of a
second member of the claudin family, claudin-19 (CLDN19), in
TALH mediated paracellular calcium and magnesium reabsorp-
tion by identifying CLDN19 mutations in patients with a renal
phenotype indistinguishable from patients affected with clau-
din-16 mutations, but with an additional severe ocular affection
[19].
Only around 10% of filtered magnesium is reabsorbed in the
DCT. However, the DCT determines the final urinary magne-
sium concentration, as no reabsorption takes place beyond this
segment [20]. Magnesium reabsorption in the DCT is active and
transcellular in nature and critically influenced by active salt
transport and cellular energy metabolism [21]. Transcellular
magnesium transport as in the intestine consists of an apical
entry step driven by the favorable electrochemical gradient
probably through a magnesium selective ion channel and an
active extrusion step on the basolateral side against the electro-
chemical gradient (Fig. 1).
Molecular genetic studies in patients with hereditary renal
magnesium wasting identified several proteins influencing
DCT mediated magnesium reabsorption. For example, patients
with loss-of-function mutations in the sodium chloride
cotransporter NCCT (SLC12A3) in addition to salt wasting
with hypokalemic alkalosis also exhibit renal magnesium
wasting and hypocalciuria [22]. The combination of magne-
sium wasting together with decreased calcium excretion
appears to be pathognomonic for impaired DCT function.
Also patients with mutations in the Na-K-ATPase gamma-
subunit as well as patients with a defect in a mitochondrial
tRNA both show impaired magnesium reabsorption in the DCT
and hypocalciuria [21,23]. Despite this progress, the molecular
components directly involved in the transcellular pathway in
the DCT remained unknown until the discovery of TRPM6 as a
component of the apical epithelial magnesium channel.
Unfortunately, the molecular identity of basolateral magnesium
extrusion is still unresolved.
3. Hypomagnesemia with secondary hypocalcemia (HSH)
Primary hypomagnesemia with secondary hypocalcemia is a
rare autosomal-recessive disease characterized by extremely low
serum magnesium levels (∼0.2 mmol/L) accompanied by
hypocalcemia (∼1.6 mmol/L). It was first described by Paunier
and colleagues in 1968 [24]. The hypocalcemia is thought to
result from an inhibition of parathyroid hormone synthesis andrelease from the parathyroid gland in the presence of profound
hypomagnesemia [25].
Affected patients typically manifest during the first months of
life. As magnesium is freely exchanged at the placenta level,
magnesium supplementation during intrauterine development is
warranted. After birth, however, magnesium levels are progres-
sively depleted until magnesium deficiency becomes clinically
manifest after several weeks to months. The clinical picture at
initial presentation usually consists of generalized seizures.
Tetany or muscle spasms are observed only in very few cases.
Relief of clinical symptoms and normalization of calcium
homeostasis is assured by immediate administration of magne-
sium via the intravenous route followed by lifelong oral
substitution of high doses of magnesium [26]. Serum magne-
sium levels usually fail to reach normal values under oral
substitution and remain in the subnormal range (around 0.5–
0.6 mmol/L). Delay in diagnosis may lead to severe neurological
deficits or can even be fatal. Daily oral magnesium doses greatly
vary between patients with a mean dose equivalent to four times
the recommended daily amounts. The main side effect of high
oral magnesium supplementation is pronounced diarrhea which
is observed in a considerable number of patients [27].
Contrasting with all other known hereditary disorders of
magnesium homeostasis, pathophysiologic studies in affected
patients using radioactive magnesium isotopes pointed to a
primary defect in intestinal magnesium absorption [28,29]. The
presence of an additional renal magnesium leak in HSH was
controversially discussed [29–31]. At last, renal magnesium
wasting in HSH patients was clearly demonstrated by using
magnesium loading tests [7].
As magnesium uptake studies using radioactive magnesium
isotopes are not available on a routine basis, measurement of
urinary magnesium excretion remains the predominant diag-
nostic tool in clinical practice. Physiologically, the kidney, in the
presence of hypomagnesemia, aims at preserving magnesium by
lowering fractional excretions below 0.5–1%, with the physio-
logical range being 3–5% [32]. Rodriguez-Soriano and cow-
orkers suggest a renal threshold for magnesium with virtually
absent renal magnesium excretion when serum magnesium
levels decrease below 0.7 mmol/L (equivalent to ∼0.5 mmol/L
(∼1.2 mg/dl) ultrafiltrable magnesium) [33]. Therefore, in HSH
patients with serum magnesium levels almost continuously in
the subnormal range, fractional excretions would be expected to
be below 1% presuming an intact renal magnesium conserva-
tion. Indeed, at initial manifestation during profound hypomag-
nesemia (SMg around 0.2 mmol/L), fractional magnesium
excretions are found to be low in HSH patients. In contrast,
during oral magnesium supplementation, fractional magnesium
excretions are inadequately increased considering that patients
are still overtly hypomagnesemic [27]. Therefore, a significant
renal magnesium leak clearly contributes to the pathogenesis of
the disease and probably prevents reaching physiologic serum
values under adequate therapy in most cases.
By using a DNA pooling strategy, Walder and co-workers
mapped a gene locus for HSH on chromosome 9q22 [34]. A
positional candidate gene approach then identified mutations in
TRPM6 as the underlying genetic defect in HSH [7,35].
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Expression studies detected the presence of TRPM6 along
the entire gastrointestinal tract as well as in kidney predomi-
nantly in the distal convoluted tubule (DCT) [35]. The expected
apical expression in the distal convoluted tubule was confirmed
by immunohistochemistry which showed a complete co-
localization with the sodium–chloride cotransporter NCCT
and also with parvalbumin and calbindin-D28K, two cytosolic
proteins that may act as intracellular magnesium buffers [10].
The TRPM6 gene comprises 39 exons and codes for large
protein of up to 2022 amino acids. Avariety of splice variants has
been identified including three alternative first exons [8].
However, the biological relevance of these multiple variants
remains unknown. The spectrum of mutations identified in HSH
includes various stop mutations, splice site mutations, frame
shift mutations, and deletions of exons (Fig. 2). These mutationsFig. 2. TRPM6 Gene and Protein. TRPM6 consists of 39 Exons spanning 167 kb of
protein harbors an ion channel region with six transmembrane domains and a puta
terminus conserved within the TRPM family, the TRP domain of unknown function
with sequence similarity to the atypical alpha kinases. TRPM6 mutations identified s
TRPM6 protein.are thought to lead to a truncated TRPM6 protein and a complete
loss-of-function [7,35,36]. Mutations leading to premature stops
of translation are distributed over the entire TRPM6 gene. From
several single amino acid mutations only two, S141L in the N-
terminus of the TRPM6 protein, and P1017R in the putative pore
region were functionally characterized (see below) [8,35,37].
TRPM6 belongs to the TRPM subfamily of transient
receptor potential (TRP) ion channels named after its founding
member melastatin. The eight members of the family are
characterized by a long conserved N-terminus of unknown
function as well as an extended C-terminus. Three TRPM cation
channels exhibit a C-terminal enzyme domain for which these
proteins have been termed “chanzymes” [38]. The phylogenetic
analysis of the TRPM subfamily based on amino acid sequence
similarities indicates four distinct groups of which one consists
of TRPM6 and its closest homologue TRPM7. Both proteins
share the unique feature of a C-terminal serine/threonine proteingenomic sequence and coding for a protein of 2022 amino acids. The TRPM6
tive pore region between the fifth and sixth transmembrane domain, a long N-
located c-terminally of the ion channel domain, and a c-terminal kinase domain
o far are indicated together with the corresponding amino acid exchanges in the
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kinase and other atypical alpha kinases [1].
Significant progress towards a functional characterization of
the two highly homologous channel kinases was recently made
by electrophysiological as well as cell biological studies on
TRPM7.
Electrophysiological characterization of TRPM7 in hetero-
logous expression systems demonstrated that TRPM7 is a
constitutively active cation channel which is inhibited by
intracellular free magnesium and magnesium ATP [2,3,39].
Consequently, it was postulated that variations in intracellular
magnesium and magnesium ATP are key physiological
mechanisms controlling TRPM7 channel activity [3,4,39].
TRPM7 is permeable to a broad range of divalent cations,
including trace metals, such as zinc, cobalt, and manganese. In
contrast to other TRPs, TRPM7 was shown to be slightly more
permeable for magnesium than for calcium [3,4,39]. In the
absence of divalent cations in the extracellular solution, TRPM7
conducts monovalent cations such as sodium [3,4,39].
More insight into the functional role of vertebrate TRPM7 at
the cellular level has been obtained using the chicken B
lymphocyte cell line DT40. DT40 cells are characterized by the
possibility for efficient gene targeting, a high frequency of
homologous recombinations and a stable phenotype, and,
therefore, are regarded as a useful model for genetic manipula-
tions in a cell system. It was shown recently that DT40 cells
lacking the chicken TRPM7 gene are not viable [4]. However,
supplementation of the cell culture medium with high levels of
Mg2+, but not Ca2+, restores the viability of mutant DT40 cells
[4]. Importantly, mammalian TRPM7 variants (wild type protein
as well as a kinase-dead mutant) were able to rescue the mutant
DT40 cell line cultured at physiological Mg2+ concentrations
[4]. Together, these data indicate a vital role of TRPM7 inMg2+
homeostasis in vertebrate cells.
Recent data controversially describe the role of the kinase
domain for TRPM7 ion channel function. While abolishing
phosphotransferase activity does obviously not impede channel
activation, deletion of the kinasemoiety leads to a suppression of
ion channel activity at physiologic intracellular magnesium
levels [4]. Therefore, Schmitz and colleagues conclude that ion
channel inhibition by intracellular magnesium is influenced by
the coordinated action of ion channel and phosphotransferase
activity [40]. Therefore, TRPM7 could potentially serve both as
a magnesium uptake mechanism and a magnesium sensor [40].
Another study recently found TRPM7 completely inactive upon
deletion of the kinase domain, probably, due to trafficking
incompetence of the truncated cation channel [5]. The same
study identified two major sites of autophosphorylation of
TRPM7 by its kinase domain (Ser1511 and Ser1567). However,
mutation of phosphorylation sites as well as of the katalytic
center of kinase left TRPM7 channel activity unaffected pointing
to a critical role of kinase structure rather than katalytic activity
for channel function [5]. Further studies are required to reconcile
this discrepancy.
But what is the physiological role of ion channel and
phosphotransferase interplay? Recently, annexin 1 was identi-
fied by Ryazanovs group as a first substrate of TRPM7 kinase[41]. Annexin 1 belongs to a family of calcium- and phos-
pholipid-binding proteins, that were originally identified as
endogenous mediators of the anti-inflammatory actions of glu-
cocorticoids, but are also implicated in the regulation of cell
growth and apoptosis [42,43]. Interestingly, phosphorylation by
TRPM7 kinase occurs at a conserved serine residue (Ser5) in the
N terminus of annexin 1, a site that is possibly specific for
TRPM7 kinase [41]. The N terminus of annexin 1 is thought to
mediate its interaction with protein ligands and membranes. As
both proteins, annexin 1 and TRPM7, have been linked to
processes of cell survival and cell growth [42,44], the authors
speculate that the regulation of cell death and proliferation by
TRPM7 involves the phosphorylation of annexin 1 by TRPM7
kinase.
The implication of TRPM7 in cellular growth and differ-
entiation is substantiated by the observations of Clark and
coworkers who identified myosin IIA heavy chain as a further
substrate of TRPM7 phosphotransferase. By interaction with the
actomyosin cytoskeleton, TRPM7 was shown to regulate cell
spreading and the formation of cell–cell adhesions [45].
The discovery of potentially differentially phosphorylated
substrates of TRPM6 and TRPM7 kinases will certainly be of
key importance to understand the physiological role of the
chanzymes in vivo.
5. Functional characterization of TRPM6
The discovery of TRPM6 mutations in HSH together with
the functional data obtained for TRPM7 instigated a functional
characterization of TRPM6. However, functional data obtained
for TRPM6 are discussed controversially.
Two groups succeeded in functionally expressing TRPM6
in heterologous expression systems [10,11]. In a collaborative
effort, the groups of B. Nilius, Leuven, and R. Bindels, Nijmegen,
successfully expressed functional TRPM6 channels in HEK293
cells and showed a somewhat higher permeability for magne-
sium when compared with TRPM7 [10]. They describe large
outwardly-rectifying whole cell currents resembling the currents
observed for TRPM7 by Nadler and colleagues [10]. The
current–voltage profile was shown to originate from small
inward currents at negative potentials carried by divalent cations
(i.e. calcium and magnesium), and large outward currents at
positive potentials reflecting efflux of monovalent cations (i.e.
sodium). In addition, extracellular divalent cations provoke a
block of inward currents carried by monovalent cations. As
magnesium more efficiently blocks monovalent inward currents
than calcium, Voets and colleagues conclude that the TRPM6
pore shows a higher affinity to magnesium than calcium
potentially indicating magnesium selectivity [10]. Influx of
magnesium through TRPM6 was also demonstrated after
intracellular depletion by increases in intracellular magnesium
using the fluorescent probe mag-fura-2 [10]. Furthermore, as
shown for TRPM7, TRPM6-induced currents exhibit a marked
sensitivity to intracellular magnesium at physiologic concentra-
tions (0.5 mmol/L).
Besides these characteristics shared between TRPM6 and
TRPM7, Li and colleagues report a number of electrophysio-
Fig. 3. Electrophysiological characterization of TRPM6/TRPM7. (A) Two-
electrode voltage clamp analysis of Xenopus oocytes injected with 10 ng of
cRNA encoding TRPM6 (red curve), TRPM7 (blue curve), or 10 ng of TRPM6
cRNA together with 10 ng of TRPM7 cRNA (black curve). Co-expression of
TRPM6 with TRPM7 results in a significant amplification of TRPM7-induced
currents. (B) Patch-clamp analysis of TRPM6/7 in HEK293 cells stablely
transfected using an ecdysone inducible gene expression system (Invitrogen).
Without induction, small endogenous TRPM7 currents are observed (green
curve). TRPM6 induction does not result in a significant increase in currents (red
curve), whereas induction of TRPM7 results in the development of large
currents with outward rectification at positive potentials (blue curve). Additional
transient expression of TRPM6 in the TRPM7 cell line leads to a significant
amplification of currents (black curve).
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including divalent cation permeation profile, pH-sensitivity and
inhibition by 2-APB with TRPM6 being less permeable for
nickel, less sensitive to extracellular pH and activated rather than
inhibited by 2-APB [11]. Most remarkably, single channel
conductance of TRPM6with 84 pS is more than twice compared
to that reported for TRPM7 (∼40 pS) [11].
Further support for divalent cation permeation through
TRPM6 monomers originate from a study of Topala and
coworkers who demonstrated modified TRPM6 permeation
characteristics by single amino acid mutations within the
putative TRPM6 pore [46]. Changing E1029 within the putative
selectivity filter of the TRPM pore between transmembrane
segments five and six (TRPM6 1028GEIDVC1033) resulted in
changes in cation permeation profile, sensitivity to ruthenium
red, and pore diameter as assessed by permeation of methyl
ammonium derivates [46]. Moreover, E1024 and D1031 were
identified as potential determinants of cation permeation as
neutralization of both residues to alanine resulted in non-
functional channels and D1031 showed a dominant-negative
effect upon co-expression with wild-type TRPM6 [46].
In contrast, other groups failed to observe measurable
currents upon TRPM6 expression. Instead, heterologous ex-
pression in different expression systems including mammalian
cells and Xenopus oocytes consistently showed an intracellular
retention of the TRPM6 protein. In line with this observation,
TRPM6 fails to rescue the lethal effect of TRPM7 deficiency in
the DT40 cell line [12]. In fact, several lines of evidence support
an essential role of TRPM7 for TRPM6 surface expression:
Co-expression with TRPM7 in HEK293 cells results in the
incorporation of TRPM6 into channel complexes at the plasma
membrane as detected by a TRPM6-specific polyclonal anti-
body, using GFP-fusion constructs and immunoblotting [8,12].
The direct and specific interaction between both proteins was
also confirmed by a static FRET (fluorescence resonance energy
transfer) strategy [8] as well as by co-immunoprecipitation of
epitope-tagged TRPM6/7 constructs [12].
Next, electrophysiological data on TRPM6/7 heteromulti-
merization obtained in Xenopus oocytes as well as in
mammalian cells shows that co-expression of TRPM6 with
TRPM7 results in a significant amplification of TRPM7-induced
currents [8,36] (Fig. 3). Currents obtained in Xenopus oocytes
exhibit the typical features observed for TRPM7 in mammalian
cells with pronounced outward rectification at positive poten-
tials. However, the reversal voltage of around −30 mV points to
the contribution to the whole cell currents of endogenously
expressed chloride channels putatively activated by calcium
entry. Therefore, oocyte currents are thought to provide a rather
indirect, but nevertheless sensitive read out of divalent cation
fluxes through the TRPM6/7 channel complex (Fig. 3).
Further support for the concept of TRPM6/7 heteromultimer-
ization originates from the analysis of the TRPM6 S141Lmutant
observed in HSH. Using immunofluorescence studies, this
mutant was found to abrogate the interaction between TRPM6
and TRPM7 resulting in intracellular retention of mutant
TRPM6 S141L. The failure of TRPM6 S141L to form hetero-
multimers with TRPM7 was also demonstrated using the FRETtechnique. In the Xenopus oocyte system, the mutant in contrast
to wildtype TRPM6 failed to increase TRPM7 induced currents
[8]. Therefore, the S141L mutation is thought to specifically
interfere with TRPM6/7 heteromultimerization presumably in
the endoplasmic reticulum. The most convincing evidence for
direct TRPM6/-7 interaction finally arises from the recent
observation that another TRPM6 mutation identified in HSH
(P1017R) exerts a strong dominant negative effect on TRPM7
function after heterologous expression in Xenopus oocytes and
mammalian cells [37].
Our findings were recently corroborated by two other groups
of investigators, thus lending further credence to the principal
concept emerging from our data on TRPM6 mutations in HSH
patients that TRPM6 and TRPM7 are functionally non-re-
dundant and play unique and indispensable biological roles
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in which TRPM7 was deleted causing growth arrest, TRPM7
deficiency cannot be complemented by heterologously
expressed TRPM6, and the latter protein requires TRPM7 for
cell surface expression [12]. Similarly, overexpression of
TRPM6 did not mimic the morphological changes of cells
(loss of adhesion and cell rounding) that were visible when
TRPM7 was expressed [47].
Surprisingly, coexpression of TRPM6with TRPM7 results in
an inhibitory effect on cell growth at low extracellular
magnesium levels which is not observed at physiologic
magnesium concentrations in the culture medium [12]. The
same study suggested that TRPM6 modulates TRPM7 activity
via phosphorylation as TRPM6 kinase was found to cross-
phosphorylate TRPM7 but not vice versa. Interestingly, a
naturally occurring TRPM7 variant (T1482I) was identified
recently lacking a putative threonine phosphorylation site [48].
TRPM7 T1482I was shown to exhibit an altered sensitivity to
intracellular magnesium resulting in decreased currents at low
intracellular magnesium levels. The authors therefore suggest
that TRPM7 sensitivity to intracellular magnesium is modulated
by phosphorylation at that threonine residue [48]. As T1482 lies
in a serine and threonine rich region between TRPM7 channel
and kinase domains which is not conserved in TRPM6, Schmitz
and colleagues hypothesize that it could also be the target of
unidirectional cross-phosphorylation of TRPM7 by TRPM6
[12]. These data together point to a model in which TRPM6
modulates TRPM7 activity by cross-phosphorylation which in
turn alters the sensitivity of TRPM7 to intracellular magnesium.
However, if this modulation of TRPM7 activity by TRPM6 is of
physiological relevance in vivo has to be determined in future
studies.
Interestingly, Li and colleagues next to comparing TRPM6
evoked currents with those observed for TRPM7 also performed
electrophysiological recordings after co-expression of both
channel kinases [11]. They provided several lines of evidence
indicating that TRPM6, TRPM7, and TRPM6/7 channels are
biophysically and pharmacologically distinguishable, and that
TRPM6, TRPM7, and TRPM6/7 form distinct ion channels
[11]. In accord with our previous observation, the TRPM6-
S141L mutant did not produce functional channels.
After coexpression of TRPM6 and TRPM7 Li and colleagues
observed a unique single channel conductance of 56 pS in
outside-out patches compared to 84 pS vs. 40 pS conductances
observed for TRPM6 and TRPM7, respectively, a finding indeed
pointing to the formation of functional heteromers with specific
pore characteristics [11]. Moreover, the finding of a single
intermediate conductance for TRPM6/7 heteromers might even
suggest a specific stoichiometry of the tetramer. In addition,
TRPM6/7 heteromers were shown to possess distinct, more or
less “intermediate” characteristics concerning the sensitivity to
protons and 2-ABP as well as specific cation permeation profile.
While the permeability to magnesium or calcium is very similar
between the three different types of channels, they differ most
strikingly in their relative permeability to nickel [11]. Such
“intermediate” properties have well been described for other
heteromultimeric ion channels including TRPV5/6 [49].As to now, we are unable to offer plausible explanations for
the discrepant findings which deserve further investigation. The
above cited studies are altogether based on data obtained in
heterologous over-expression systems, and, subsequently, do
not necessarily reflect physiological properties of epithelial
magnesium channels in vivo. Indeed, as suggested by Topala
et al., surface expression of TRPM6 might be influenced by the
presence of endogenous TRPM7 in HEK293 cells. In this
context, the data of Li and colleagues, who suggest the
possibility of TRPM6 homomer as well as TRPM6/7 heteromer
formation at least in such artificial systems, may also be
interpreted as an effect of different degrees of TRPM7
expression on TRPM6 function. Although we cannot exclude,
that a specific overexpression strategy or chemical chaperone
may overcome an intracellular retention of TRPM6, the specific
interaction of TRPM6 with TRPM7, reproduced in different
expression systems, most likely reflects physiologic TRPM6
function as a subunit of TRPM6/7 channel complexes.
Additional studies are surely required to validate the functional
significance of TRPM6/7 assembly in native cells.
6. Regulation of TRPM6 and TRPM7 in vivo
Whereas TRPM7 putatively serves as an ubiquitous cellular
magnesium uptake mechanism, the hypomagnesemic pheno-
type of HSH patients together with the expression pattern of
TRPM6 suggest that TRPM6 – potentially in cooperation with
TRPM7 – accomplishes the uptake of magnesium through the
epithelial barrier in intestine and kidney. One can easily imagine
that this specialized function requires distinct qualities in
activation and regulation of the ion channel complex. Recent
data by the Bindels group indeed point to a differential
regulation of the two channel kinases in vivo [9,50]. Dietary
magnesium restriction results in magnesium deficiency and
hypomagnesemia in mice which in turn leads to magnesium
conservation in the kidney. This physiological renal response to
hypomagnesemia goes along with an upregulated expression of
TRPM6 in the DCT [9]. In contrast, renal TRPM7 expression is
unaffected by magnesium deficiency. In the intestine, TRPM6
expression appears to be positively regulated by dietary
magnesium content as increasing dietary magnesium leads to
increased TRPM6 mRNA expression in mice [9]. Furthermore,
TRPM6 expression in mouse kidney was also found to be
regulated by 17beta-estradiol but not by parathyroid hormone
or 1,25-hydroxy-vitamin D. In line with these data, TRPM6
expression was shown to be significantly reduced in ovar-
iectomized rats and normalized after 17beta-estradiol treatment
[9].
Renal magnesium handling in the DCT depends on acid–
base status in a way that metabolic acidosis leads to renal
magnesium wasting whereas metabolic alkalosis preserves
magnesium via increased distal tubular reabsorption [15]. This
might (at least in part) be explained by a downregulation of
TRPM6 expression going along with renal magnesium wasting
in mice subjected to metabolic acidosis by ammonium chloride
loading [50]. Metabolic alkalosis provoked by sodium bicarbo-
nate lead to the opposite effects in mice [50].
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In conclusion, the identification of TRPM6 and TRPM7 for
the first time provides insight into cellular magnesium transport
at the molecular level. The vital role of TRPM7 for cellular
magnesium homeostasis, the phenotype of HSH patients with
defective TRPM6, and the rapidly growing set of functional
data obtained for both TRPM proteins point to a critical role of
the two channel kinases for cellular magnesium uptake.
Currently, data concerning the relevance of TRPM6 homomer
formation for epithelial magnesium transport in vivo is still
inconclusive. Meanwhile, TRPM6 heteromer formation with
TRPM7 has been observed by several independent groups and
distinct properties of TRPM6/7 heteromers concerning bio-
chemical and electrophysiological properties have been
described. Moreover, a mutual interaction of both TRPM
members putatively via their kinase domains appears to be
critical for the magnesium sensitivity of the channel complex
and for the putative negative feed-back regulation by intracel-
lular magnesium. As data on TRPM6 homo- and/or heteromer
formation mainly originate from artificial overexpression
systems, future studies will have to address the functional
significance of TRPM6/7 assembly for epithelial magnesium
transport in vivo. For this purpose, the combined genetic and
functional analysis of TRPM6 mutants observed in HSH
patients represents a favourable opportunity.
References
[1] L.V. Riazanova, K.S. Pavur, A.N. Petrov, M.V. Dorovkov, A.G. Riazanov,
Novel type of signaling molecules: protein kinases covalently linked to ion
channels, Mol. Biol. (Mosk.) 35 (2001) 321–332.
[2] L.W. Runnels, L. Yue, D.E. Clapham, TRP-PLIK, a bifunctional protein
with kinase and ion channel activities, Science 291 (2001) 1043–1047.
[3] M.J. Nadler, M.C. Hermosura, K. Inabe, A.L. Perraud, Q. Zhu, A.J.
Stokes, T. Kurosaki, J.P. Kinet, R. Penner, A.M. Scharenberg, A. Fleig,
LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell
viability, Nature 411 (2001) 590–595.
[4] C. Schmitz, A.L. Perraud, C.O. Johnson, K. Inabe, M.K. Smith, R. Penner,
T. Kurosaki, A. Fleig, A.M. Scharenberg, Regulation of vertebrate cellular
Mg2+ homeostasis by TRPM7, Cell 114 (2003) 191–200.
[5] M. Matsushita, J.A. Kozak, Y. Shimizu, D.T. McLachlin, H. Yamaguchi,
F.Y. Wei, K. Tomizawa, H. Matsui, B.T. Chait, M.D. Cahalan, A.C.
Nairn, Channel function is dissociated from the intrinsic kinase activity
and autophosphorylation of TRPM7/ChaK1, J. Biol. Chem. 280 (2005)
20793–20803.
[6] P. Demeuse, R. Penner, A. Fleig, TRPM7 channel is regulated by
magnesium nucleotides via its kinase domain, J. Gen. Physiol. 127 (2006)
421–434.
[7] R.Y. Walder, D. Landau, P. Meyer, H. Shalev, M. Tsolia, Z. Borochowitz,
M.B. Boettger, G.E. Beck, R.K. Englehardt, R. Carmi, V.C. Sheffield,
Mutation of TRPM6 causes familial hypomagnesemia with secondary
hypocalcemia, Nat. Genet. 31 (2002) 171–174.
[8] V. Chubanov, S. Waldegger, M. Mederos y Schnitzler, H. Vitzthum, M.C.
Sassen, H.W. Seyberth, M. Konrad, T. Gudermann, Disruption of TRPM6/
TRPM7 complex formation by a mutation in the TRPM6 gene causes
hypomagnesemia with secondary hypocalcemia, Proc. Natl. Acad. Sci.
U. S. A. 101 (2004) 2894–2899.
[9] W.M. Groenestege, J.G. Hoenderop, L. van den Heuvel, N. Knoers, R.J.
Bindels, The epithelial Mg2+ channel transient receptor potential
melastatin 6 is regulated by dietary Mg2+ content and estrogens, J. Am.
Soc. Nephrol. 17 (2006) 1035–1043.[10] T. Voets, B. Nilius, S. Hoefs, A.W. van der Kemp, G. Droogmans, R.J.
Bindels, J.G. Hoenderop, TRPM6 forms the Mg2+ influx channel
involved in intestinal and renal Mg2+ absorption, J. Biol. Chem. 279
(2004) 19–25.
[11] M. Li, J. Jiang, L. Yue, Functional characterization of homo- and
heteromeric channel kinases TRPM6 and TRPM7, J. Gen. Physiol. 127
(2006) 525–537.
[12] C. Schmitz, M.V. Dorovkov, X. Zhao, B.J. Davenport, A.G. Ryazanov,
A.L. Perraud, The channel kinases TRPM6 and TRPM7 are functionally
nonredundant, J. Biol. Chem. 280 (2005) 37763–37771.
[13] K.D. Fine, C.A. Santa Ana, J.L. Porter, J.S. Fordtran, Intestinal absorption
of magnesium from food and supplements, J. Clin. Invest. 88 (1991)
396–402.
[14] G.A. Quamme, Magnesium homeostasis and renal magnesium handling,
Miner. Electrolyte Metab. 19 (1993) 218–225.
[15] L.J. Dai, G. Ritchie, D. Kerstan, H.S. Kang, D.E. Cole, G.A. Quamme,
Magnesium transport in the renal distal convoluted tubule, Physiol. Rev.
81 (2001) 51–84.
[16] D. Kerstan, G.A. Quamme, Physiology and pathophysiology of intestinal
absorption of magnesium, in: S.G. Massry, H. Morii, Y. Nishizawa
(Eds.), Calcium in Internal Medicine, Springer-Verlag, London, 2002,
pp. 171–183.
[17] C. de Rouffignac, G.A. Quamme, Renal magnesium handling and its
hormonal control, Physiol. Rev. 74 (1994) 305–322.
[18] D.B. Simon, Y. Lu, K.A. Choate, H. Velazquez, E. Al-Sabban, M. Praga,
G. Casari, A. Bettinelli, G. Colussi, J. Rodriguez-Soriano, D. McCredie, D.
Milford, S. Sanjad, R.P. Lifton, Paracellin-1, a renal tight junction protein
required for paracellular Mg2+ resorption, Science 285 (1999) 103–106.
[19] M. Konrad, A. Schaller, D. Seelow, A.V. Pandey, S. Waldegger, A.
Lesslauer, H. Vitzthum, Y. Suzuki, J.M. Luk, C. Becker, K.P.
Schlingmann, M. Schmid, J. Rodriguez-Soriano, G. Ariceta, F. Cano, R.
Enriquez, H. Juppner, S.A. Bakkaloglu, M.A. Hediger, S. Gallati, S.C.
Neuhauss, P. Nurnberg, S. Weber, Mutations in the tight-junction gene
claudin 19 (CLDN19) are associated with renal magnesium wasting, renal
failure, and severe ocular involvement, Am. J. Hum. Genet. 79 (2006)
949–957.
[20] G.A. Quamme, Renal magnesium handling: new insights in understanding
old problems, Kidney Int. 52 (1997) 1180–1195.
[21] F.H. Wilson, A. Hariri, A. Farhi, H. Zhao, K.F. Petersen, H.R. Toka, C.
Nelson-Williams, K.M. Raja, M. Kashgarian, G.I. Shulman, S.J.
Scheinman, R.P. Lifton, A cluster of metabolic defects caused by mutation
in a mitochondrial tRNA, Science 306 (2004) 1190–1194.
[22] D.B. Simon, C. Nelson-Williams, M.J. Bia, D. Ellison, F.E. Karet, A.M.
Molina, I. Vaara, F. Iwata, H.M. Cushner, M. Koolen, F.J. Gainza, H.J.
Gitelman, R.P. Lifton, Gitelman's variant of Bartter's syndrome, inherited
hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive
Na-Cl cotransporter, Nat. Genet. 12 (1996) 24–30.
[23] I.C. Meij, J.B. Koenderink, H. van Bokhoven, K.F. Assink, W.T.
Groenestege, J.J. de Pont, R.J. Bindels, L.A. Monnens, L.P. van den
Heuvel, N.V. Knoers, Dominant isolated renal magnesium loss is caused
by misrouting of the Na(+),K(+)-ATPase gamma-subunit, Nat. Genet. 26
(2000) 265–266.
[24] L. Paunier, I.C. Radde, S.W. Kooh, P.E. Conen, D. Fraser, Primary
hypomagnesemia with secondary hypocalcemia in an infant, Pediatrics 41
(1968) 385–402.
[25] C.S. Anast, J.M. Mohs, S.L. Kaplan, T.W. Burns, Evidence for parathyroid
failure in magnesium deficiency, Science 177 (1972) 606–608.
[26] H. Shalev, M. Phillip, A. Galil, R. Carmi, D. Landau, Clinical presentation
and outcome in primary familial hypomagnesaemia, Arch. Dis. Child 78
(1998) 127–130.
[27] K.P. Schlingmann, M.C. Sassen, S. Weber, U. Pechmann, K. Kusch, L.
Pelken, D. Lotan, M. Syrrou, J.J. Prebble, D.E. Cole, D.L. Metzger, S.
Rahman, T. Tajima, S.G. Shu, S. Waldegger, H.W. Seyberth, M. Konrad,
Novel TRPM6 mutations in 21 families with primary hypomagnesemia
and secondary hypocalcemia, J. Am. Soc. Nephrol. 16 (2005) 3061–3069.
[28] I. Lombeck, F. Ritzl, H.G. Schnippering, H. Michael, H.J. Bremer, L.E.
Feinendegen, W. Kosenow, Primary hypomagnesemia: I. Absorption
studies, Z. Kinderheilkd. 118 (1975) 249–258.
821K.P. Schlingmann et al. / Biochimica et Biophysica Acta 1772 (2007) 813–821[29] P.J. Milla, P.J. Aggett, O.H. Wolff, J.T. Harries, Studies in primary
hypomagnesaemia: evidence for defective carrier-mediated small intestinal
transport of magnesium, Gut 20 (1979) 1028–1033.
[30] J.H. Stromme, J. Steen-Johnsen, K. Harnaes, F. Hofstad, P. Brandtzaeg,
Familial hypomagnesemia—A follow-up examination of three patients
after 9 to 12 years of treatment, Pediatr. Res. 15 (1981) 1134–1139.
[31] H. Matzkin, D. Lotan, H. Boichis, Primary hypomagnesemia with a
probable double magnesium transport defect, Nephron 52 (1989) 83–86.
[32] R.A. Sutton, S. Domrongkitchaiporn, Abnormal renal magnesium
handling, Miner. Electrolyte Metab. 19 (1993) 232–240.
[33] J. Rodriguez-Soriano, A. Vallo, M. Garcia-Fuentes, Hypomagnesaemia of
hereditary renal origin, Pediatr. Nephrol. 1 (1987) 465–472.
[34] R.Y. Walder, H. Shalev, T.M. Brennan, R. Carmi, K. Elbedour, D.A. Scott,
A. Hanauer, A.L. Mark, S. Patil, E.M. Stone, V.C. Sheffield, Familial
hypomagnesemia maps to chromosome 9q, not to the X chromosome:
genetic linkage mapping and analysis of a balanced translocation
breakpoint, Hum. Mol. Genet. 6 (1997) 1491–1497.
[35] K.P. Schlingmann, S. Weber, M. Peters, L. Niemann Nejsum, H. Vitzthum,
K. Klingel, M. Kratz, E. Haddad, E. Ristoff, D. Dinour, M. Syrrou, S.
Nielsen, M. Sassen, S. Waldegger, H.W. Seyberth, M. Konrad, Hypomag-
nesemia with secondary hypocalcemia is caused by mutations in TRPM6, a
new member of the TRPM gene family, Nat. Genet. 31 (2002) 166–170.
[36] K.P. Schlingmann, T. Gudermann, A critical role of TRPM channel-kinase
for human magnesium transport, J. Physiol. 566 (2005) 301–308.
[37] V. Chubanov, K.P. Schlingmann, J. Waring, J. Heinzinger, S. Kaske, S.
Waldegger, Y.S.M. Mederos, T. Gudermann, Hypomagnesemia with
secondary hypocalcemia due to a missense mutation in the putative pore-
forming region of TRPM6, J. Biol. Chem. 282 (2007) 7656–7667.
[38] C. Montell, Mg2+ homeostasis: the Mg2+nificent TRPM chanzymes,
Curr. Biol. 13 (2003) R799–R801.
[39] M.K. Monteilh-Zoller, M.C. Hermosura, M.J. Nadler, A.M. Scharenberg,
R. Penner, A. Fleig, TRPM7 provides an ion channel mechanism for
cellular entry of trace metal ions, J. Gen. Physiol. 121 (2003) 49–60.
[40] C. Schmitz, A.L. Perraud, A. Fleig, A.M. Scharenberg, Dual-function ionchannel/protein kinases: novel components of vertebrate magnesium
regulatory mechanisms, Pediatr. Res. 55 (2004) 734–737.
[41] M.V. Dorovkov, A.G. Ryazanov, Phosphorylation of annexin I by TRPM7
channel-kinase, J. Biol. Chem. 279 (2004) 50643–50646.
[42] M. Perretti, E. Solito, Annexin 1 and neutrophil apoptosis, Biochem. Soc.
Trans. 32 (2004) 507–510.
[43] U. Rescher, V. Gerke, Annexins-unique membrane binding proteins with
diverse functions, J. Cell Sci. 117 (2004) 2631–2639.
[44] M. Aarts, K. Iihara, W.L. Wei, Z.G. Xiong, M. Arundine, W. Cerwinski,
J.F. MacDonald, M. Tymianski, A key role for TRPM7 channels in anoxic
neuronal death, Cell 115 (2003) 863–877.
[45] K. Clark, M. Langeslag, B. van Leeuwen, L. Ran, A.G. Ryazanov, C.G.
Figdor, W.H. Moolenaar, K. Jalink, F.N. van Leeuwen, TRPM7, a novel
regulator of actomyosin contractility and cell adhesion, EMBO J. 25
(2006) 290–301.
[46] C.N. Topala, W.T. Groenestege, S. Thebault, D. van den Berg, B. Nilius,
J.G. Hoenderop, R.J. Bindels, Molecular determinants of permeation
through the cation channel TRPM6, Cell Calcium (2006) (Electronic
publication ahead of print).
[47] L.T. Su, M.A. Agapito, M. Li, W.T. Simonson, A. Huttenlocher, R. Habas,
L. Yue, L.W. Runnels, TRPM7 regulates cell adhesion by controlling
the calcium-dependent protease calpain, J. Biol. Chem. 281 (2006)
11260–11270.
[48] M.C. Hermosura, H. Nayakanti, M.V. Dorovkov, F.R. Calderon, A.G.
Ryazanov, D.S. Haymer, R.M. Garruto, A TRPM7 variant shows altered
sensitivity to magnesium that may contribute to the pathogenesis of two
Guamanian neurodegenerative disorders, Proc. Natl. Acad. Sci. U. S. A.
102 (2005) 11510–11515.
[49] J.G. Hoenderop, T. Voets, S. Hoefs, F. Weidema, J. Prenen, B. Nilius, R.J.
Bindels, Homo- and heterotetrameric architecture of the epithelial Ca2+
channels TRPV5 and TRPV6, EMBO J. 22 (2003) 776–785.
[50] T. Nijenhuis, K.Y. Renkema, J.G. Hoenderop, R.J. Bindels, Acid–base
status determines the renal expression of Ca2+ and Mg2+ transport
proteins, J. Am. Soc. Nephrol. 17 (2006) 617–626.
